Second Sight Medical Products, Inc. develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals.
+ 1 more risk
Flawless balance sheet and overvalued.
Share Price & News
How has Second Sight Medical Products's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: EYES's share price has been volatile over the past 3 months.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: EYES underperformed the US Medical Equipment industry which returned 12.7% over the past year.
Return vs Market: EYES underperformed the US Market which returned 4.6% over the past year.
Price Volatility Vs. Market
How volatile is Second Sight Medical Products's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall StDoes Second Sight Medical Products, Inc.'s (NASDAQ:EYES) CEO Pay Matter?
2 months ago | Simply Wall StDid Changing Sentiment Drive Second Sight Medical Products's (NASDAQ:EYES) Share Price Down A Disastrous 97%?
3 months ago | Simply Wall StDoes Second Sight Medical Products, Inc. (NASDAQ:EYES) Have A High Beta?
Is Second Sight Medical Products undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate EYES's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate EYES's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: EYES is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.
PE vs Market: EYES is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate EYES's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: EYES is good value based on its PB Ratio (2.2x) compared to the US Medical Equipment industry average (3.7x).
How is Second Sight Medical Products forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Second Sight Medical Products has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine Second Sight Medical Products's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Explore growth companies in the Healthcare industry.
How has Second Sight Medical Products performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: EYES is currently unprofitable.
Growing Profit Margin: EYES is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: EYES is unprofitable, and losses have increased over the past 5 years at a rate of -4.2% per year.
Accelerating Growth: Unable to compare EYES's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EYES is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (7.3%).
Return on Equity
High ROE: EYES has a negative Return on Equity (-461.75%), as it is currently unprofitable.
How is Second Sight Medical Products's financial position?
Financial Position Analysis
Short Term Liabilities: EYES's short term assets ($13.1M) exceed its short term liabilities ($7.0M).
Long Term Liabilities: EYES's short term assets ($13.1M) exceed its long term liabilities ($2.4M).
Debt to Equity History and Analysis
Debt Level: EYES is debt free.
Reducing Debt: EYES had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: EYES has sufficient cash runway for 5 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: EYES is forecast to have sufficient cash runway for 5 months based on free cash flow estimates, but has since raised additional capital.
What is Second Sight Medical Products's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate EYES's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate EYES's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if EYES's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if EYES's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of EYES's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Matt Pfeffer (61yo)
Mr. Matthew J. Pfeffer, also known as Matt, CPA, serves as an Acting Chief Executive Officer of Second Sight Medical Products, Inc. since March 27, 2020 and serves as its Director since May 2015. Mr. Pfeff ...
|Acting CEO & Director||0.17yr||US$84.00k||0.064% $15.4k|
|CFO & Corporate Secretary||2.17yrs||US$480.67k||0.0076% $1.8k|
|no data||no data||no data|
|Chief Strategy & Business Development Officer||2yrs||US$615.76k||0.013% $3.1k|
|Founder & President of In-Site Communications and Investor Relations for Second Sight||no data||no data||no data|
Experienced Management: EYES's management team is considered experienced (2 years average tenure).
|Acting CEO & Director||0.17yr||US$84.00k||0.064% $15.4k|
|Independent Director||17.33yrs||US$90.00k||0.062% $15.0k|
|Independent Director||22.33yrs||US$68.00k||0.072% $17.4k|
|Independent Non-Executive Chairman||2.17yrs||US$70.00k||27% $6.5m|
Experienced Board: EYES's board of directors are considered experienced (5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 49.2%.
Second Sight Medical Products, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Second Sight Medical Products, Inc.
- Ticker: EYES
- Exchange: NasdaqCM
- Founded: 1998
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$24.084m
- Shares outstanding: 23.16m
- Website: https://www.secondsight.com
Number of Employees
- Second Sight Medical Products, Inc.
- 12744 San Fernando Road
- Suite 400
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|EYES||NasdaqCM (Nasdaq Capital Market)||Yes||Common Stock||US||USD||Nov 2014|
|24PA||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Nov 2014|
Second Sight Medical Products, Inc. develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. It also offers Argus II Retinal Prosthesis System for treating retinitis pigmentosa. The company was founded in 1998 and is headquartered in Sylmar, California.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/05/27 02:14|
|End of Day Share Price||2020/05/26 00:00|